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Those randomized to the intervention group increased their 6-minute
walk distance in meters signiﬁcantly (357.4 to 399.8 vs 353.3 to 342.2
for those in the control group; mean difference, 53.5; P < .001). There
were also increases in maximum treadmill walking time (intervention,
7.91 to 9.44 minutes vs control, 7.56 to 8.09 minutes; mean difference,
1.01 minutes; P ¼ .04). Accelerometer-measured physical activity over 7
days also increased in the intervention group vs the control group (P ¼
.03). There were also signiﬁcant improvements in the Walking Impairment
Questionnaire distance score (P ¼ .003) and Walking Impairment Ques-
tionnaire speed score (P ¼ .004).
Comment: The study indicates that home-based exercise can be
effective in patients with PAD. It does not indicate that home-based exercise
has equal effectiveness to supervised exercise programs, because the two
were not directly compared. Nevertheless, until supervised exercise becomes
a beneﬁt of insurance coverage, the data should encourage physicians to
recommend home-based exercise therapy in their patients with PAD.
Use of Glucocorticoids and Risk of Venous Thromboembolism: A
Nationwide Population-Based Case-Control Study
Johannesdottir SA, Horvath-Puho E, Dekkers OM, et al. JAMA Intern
Med 2013;173:743-52.
Conclusions: Glucocorticoid use increases the risk of venous throm-
boembolism (VTE).
Summary: It is known that excess endogenous cortisol increases VTE
risk. Whether this risk applies to exogenous use of glucocorticoids is
unclear, however, potentially clinically important. The authors point out
that in Denmark, the country of origin of this study, 3.5% of the population
redeemed a prescription for systemic glucocorticoids in 2010 (Danish
Medicines Agency). Given the incidence of VTE and the prevalence of
glucocorticoid use, any association between VTE and glucocorticoid use
has important implications. The authors therefore decided to examine the
association between exogenous glucocorticoid use and VTE. This was
a population case-control study using a nationwide database from
Denmark. The authors identiﬁed 38,765 VTE cases from the period of
January 1, 2005, through December 31, 2011. Risk matched sampling
by birth year and sex was used to select 387,650 controls from the general
population. The VTE diagnosis date for the case was the index date for
cases and matched controls. Patients who had ﬁlled a glucocorticoid
prescription were classiﬁed by the time the prescription was ﬁlled, #90
days, 91 to 365 days, and >365 days before the index VTE date. Such
patients were classiﬁed as present, recent, and former users of glucocorti-
coids, respectively. Present users were subdivided into new (ﬁrst-ever
prescription <90 days before the index date) and continuing users (others).
Analysis was performed using conditional logistic regression adjusted for
VTE risk factors to estimate incidence rate ratios (IRRs) and 95% conﬁ-
dence intervals (CIs) for glucocorticoid users vs nonusers. VTE risk was
increased by systemic glucocorticoids in present (adjusted IRR, 2.31; 95%
CI, 2.18-2.45), new (3.06; 2.77-3.38), continuing (2.02; 1.88-2.17),
and recent (1.18; 1.10-1.26) users but not in former users (0.94; 0.90-
0.99). Adjusted IRR increased from 1.00 (95% CI, 0.93-1.07) for a prednis-
olone-equivalent cumulative dose of #10 mg to 1.98 (95% CI, 1.78-2.20)
for >1000 to 2000 mg, and to 1.60 (95% CI, 1.49-1.71) for doses >2000
mg. New use of inhaled (adjusted IRR, 2.21; 95% CI, 1.72-2.86) and intes-
tinal-acting (adjusted IRR, 2.17; 95% CI, 1.27-3.71) glucocorticoids also
increased VTE risk.
Comment: Of course, many of the disease processes for which gluco-
corticoids are prescribed may, in themselves, increase VTE risk. However,
this extensive analysis found increased risk for not only systemic glucocorti-
coids but also inhaled and intestinal-acting glucocorticoids, and a causal link
is further suggested by higher risk with new users, and with higher doses.
These observations, along with adjustment for confounding variables,
strongly suggest that the authors’ conclusion is correct that glucocorticoid
use increases the risk of VTE.
Ambulatory Blood Pressure Changes After Renal Sympathetic
Denervation in Patients with Resistant Hypertension
Mahfoud F, Ukena C, Schmieder RE, et al. Circulation 2013;124:132-40.
Conclusions: Ofﬁce blood pressures are reduced and relevant aspects
of ambulatory blood pressure (BP) monitoring (APBM) are improved after
renal sympathetic denervation in patients with true-treatment resistant
hypertension.
Summary: Hypertensive patterns and methods of assessing BP appear
to be important in the relationship between hypertension and cardiovascular
morbidity and mortality. Guidelines recommend ABPM for patients with
resistant hypertension. This is to exclude pseudohypertension and accurately
assess BP control according to treatment. ABPM, with 24-hour day-and-night average BP values, correlates better than ofﬁce BP values with hyper-
tensive or diabetic end-organ damage (Mancia G et al, Hypertension
2000;36:894-900). In addition, nighttime BP correlates more closely
with cardiovascular morbidity and mortality than daytime BP (Fagard RH
et al, Hypertension 2008;51:55-61). Finally, high nighttime BP and non-
dipping patterns of hypertension have been associated with increased
sympathetic activity in hypertensive patients (Grassi G et al, Hypertension
2008;52:925-31). Renal sympathetic denervation (RDN) reduces ofﬁce
systolic and diastolic BPs in patients with resistant hypertension (Esler
MD et al, Lancet 2010;376:1903-9). The purpose of this study was to
investigate the effects of RDN on out-of-ofﬁce BP using 24-hour ABPM.
The study represents the largest cohort of patients with true resistant and
pseudoresistant hypertension analyzed thus far. A total of 346 uncontrolled
hypertensive patients were separated according to daytime ambulatory BP
monitoring into 303 with true resistant BP (ofﬁce systolic BP [SBP] 172
6 22 mm Hg; 24-hour SBP 154 6 16 mm Hg) and 43 with pseudoresist-
ant hypertension (ofﬁce SBP 161 6 20.3 mm Hg; 24-hour SBP 121 6 20
mm Hg). Patients were from 10 centers and were studied at 3, 6, and 12
months of follow-up after RDN. In follow-up, ofﬁce SBP was reduced by
21.5/23.7/27.3 mm Hg, ofﬁce diastolic BP by 8.9/9.5/11.7 mm Hg,
and pulse pressure by 13.4/14.2/14.9 mm Hg (n ¼ 245/236/90; P for
all <.001), respectively, at 3, 6, and 12 months. In patients with true treat-
ment resistance, there was a signiﬁcant reduction with RDN in 24-hour SBP
(0.1/10.2/11.7) and minimum SBP (6.0/9.4/13.1 mm Hg; P
< .001) at 3, 6, and 12 months, respectively. In pseudoresistant patients,
RDN had no effect on ambulatory BP; however, ofﬁce BP was reduced
to a similar extent. RDN was equally effective in reducing BP in different
subgroups of patients. Ofﬁce SBP at baseline was the only independent
correlate of BP response.
Comment: The study addressed concerns that RDN might not as
effectively reduce ambulatory BP as it does ofﬁce BP. Results of the study
are not entirely unexpected. The Symplicity study of resistant hypertension
and RDN did not speciﬁcally exclude pseudoresistant hypertension (Esler
MD et al, Lancet 2010;376:1903-9). However, only w12% of the patients
in the Symplicity study apparently had pseudoresistant hypertension. As
treatment with RDN for resistant hypertension potentially moves toward
application out of clinical trials, it will be important for clinicians to be aware
that only patients with truly resistant hypertension, and not those with
“white-coat syndrome,” be considered for RDN.
Endovascular Repair Versus Open Repair of Ruptured Abdominal
Aortic Aneurysms: A Multicenter Randomized Controlled Trial
Reimerink JJ, Hoornweg LL, Vahl AC, and the Amsterdam Acute
Aneurysm Trial Collaborators. Ann Surg 2013;258:248-56.
Conclusions: There is no difference in outcome of treatment of
ruptured abdominal aortic aneurysm (RAAA) in rates of death and severe
complication for those patients treated with endovascular (EVAR) or
open repair (OR).
Summary: In recent years, treatment of RAAA with EVAR has
emerged as an alternative to OR. Support for the hypothesis that EVAR
reduces mortality in patients with RAAA vs those treated with OR comes
from observational and population-based studies (Veith FJ, Ann Surg
2009;250:818-24; and Giles KA, J Endovasc Ther 2009;16:554-64).
However, to date, no signiﬁcant randomized trial data has been available
comparing EVAR vs OR for RAAA. A single previous trial was terminated
after randomizing 32 patients (Hinchliffe RJ et al, Eur J Vasc Endovasc Surg
2006;32:506-13). The Amsterdam Acute Aneurysm Trial was designed
with the hypothesis that EVAR would reduce mortality and severe compli-
cations compared with OR for treatment of RAAA. The study was conduct-
ed in the greater Amsterdam area (1.24 million inhabitants and 10
hospitals). Three hospitals, consisting of two academic medical centers
and a teaching hospital, were trial centers for this study. The trial centers
provided alternating around-the-clock RAAA service. The other seven
regional hospitals agreed to participate in the trial by transferring patients
with suspected RAAA to one of the trial centers if possible. They also
provided data on all patients who presented with an RAAA. After diagnosis,
anatomic suitability for EVAR based on computed tomography angiog-
raphy and clinical suitability for OR was documented by the vascular
surgeon and the radiologist. Patients suitable for both were then random-
ized. All patients in the trial region with proven RAAA were included in
a prospective parallel cohort. The primary end point of the study was the
composite of death and severe complications at 30 days. Between April
2004 and February 2011, 520 patients were identiﬁed with RAAA. Of these
patients, 365 were excluded from potential randomization because of
anatomy unfavorable for EVAR, another 71 were not evaluated by
computed tomography scan, and 54 were not referred to a trial center.
This left 155 with favorable anatomy who could potentially be randomized.
An additional 39 patients, however, were excluded as unﬁt for OR (n ¼ 16),
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computed tomography angiography (n ¼ 7), or refused surgery (n ¼ 5).
This left 116 patients for randomization. The primary end point rate was
42% for EVAR and 47% for OR (absolute risk reduction, 5.4%; 95% conﬁ-
dence interval [CI], 13% to 23%]. The 30-day mortality was 21% in
patients assigned to EVAR compared with 25% for OR (absolute risk reduc-
tion, 4.4%; 95% CI, 11% to 20%). The mortality was 30% (95% CI, 26%-
35%) in all surgically treated patients in the nonrandomized cohort and was
26% (95% CI, 20%-32%) in patients with unfavorable anatomy for EVAR
treated by OR at trial centers.
Comment: The 30-day mortality for open repair in this study was
<30%, considerably lower than the 48.5% postulated before the study. A
subanalysis by the authors suggests that excluding patients highly unstable
for OR was not the reason for the unanticipated low operative mortality
of OR. It appears that OR in centers of excellence may be a better operation
for RAAA now than in the past. A combination of the improved OR for
RAAA and the large percentage of patients with RAAA unsuitable for
conventional EVAR suggests the effect of EVAR on overall outcomes for
treatment of RAAA may be less, and perhaps considerably less, than previ-
ously suggested.
Long-Term Clinical Effectiveness of Supervised Exercise Therapy
Versus Endovascular Revascularization for Intermittent Claudication
from a Randomized Clinical Trial
Fakhry F, Rouwet EV, den Hoed PT, et al. Br J Surg 2013;100:1164-71.
Conclusions: Over the long-term, supervised exercise therapy
(SET)-ﬁrst or endovascular revascularization (ER) therapy-ﬁrst treatment
strategies are equally effective in improving the quality of life and func-
tional performance in patients with intermittent claudication. There are
signiﬁcantly higher numbers of total invasive interventions in the ER-ﬁrst
group. This supports a SET-ﬁrst treatment strategy for intermittent
claudication.
Summary: SET and ER both improve walking performance and
quality of life in patients with intermittent claudication (Spronk S et al, Radi-
ology 2005;235:833-42; and Watson L et al, Cochrane Database Syst Rev
2008;CD000990). The Comparing Exercise Therapy with Angioplasty for
Claudication (CETAC) Trial (Spronk S et al, Radiology 2009;250:586-95)
and a systematic review comparing ER and SET for treatment of intermit-
tent claudication concluded that SET and ER were equally effective after
12 months (Frans FA et al, Br J Surg 2012;99:16-28). The current report
represents an attempt to provide longer follow-up of the CETAC trial to
provide an estimate of long-term clinical effectiveness of a SET-ﬁrst or an
ER-ﬁrst treatment strategy for patients with intermittent claudication.
CETAC was a single-center randomized trial that compared SET vs ER
as the initial treatment for patients with intermittent claudication. A total
of 151 patients were randomly assigned to SET (n ¼ 75) or ER (n ¼
76). After a median follow-up of w7 years (range, 0.07-9.17 years), there
were 17 deaths in the SET group and 15 in the ER group. Completeness
of long-term follow-up was 71% in the SET group and 84% in the ER group
(36 patients available for review in the SET group and 47 in the ER group).
Outcome measures were functional performance (pain-free maximum
walking distance, ankle-brachial pressure index), quality of life, and the
number of secondary interventions measured at baseline and at w7 years
of follow-up. Repeated-measurement and Kaplan-Meier methods were
used for data analyses. Data were analyzed on an intention-to-treat basis.
After 7 years, functional performance (P < .001) and quality of life (P <
.005) improved after both SET and ER. The number of secondary interven-
tions was higher in the SET group (P ¼ .001). The total number of endo-
vascular and surgical interventions (primary and secondary) was signiﬁcantly
higher with the ER-ﬁrst strategy, 64 interventions in the SET group and
121 in the ER group (P < .001). There were two minor amputations in
the SET group and three major amputations in the ER group.
Comment: The study has some limitations in that not all patients were
available for long-term follow-up, and the mortality and attrition ratedecreased the power to detect small differences between the SET and ER
groups. In addition, the authors did not collect information on regular exer-
cise performed after the trial. Only endovascular and surgical procedures were
considered secondary interventions. Nevertheless, the study still strongly
argues that to minimize total procedures in patients with intermittent claudi-
cation, a SET-ﬁrst rather than ER-ﬁrst treatment strategy is preferred.
Systematic Review of Exercise Training or Percutaneous Transluminal
Angioplasty for Intermittent Claudication
Frans FA, Bipat S, Reekers JA, et al. Br J Surg 2012;99:16-28.
Conclusions: The combination of percutaneous transluminal angio-
plasty (PTA) and exercise therapy (ET) may be superior to ET or PTA alone
for treatment of intermittent claudication.
Summary: One goal in patients with intermittent claudication is to
improve their walking distance with the thought that this will subsequently
improve their quality of life. Percutaneous transluminal angioplasty (PTA),
surgery, drugs, and exercise therapy (ET) all can improve symptoms in
patients with intermittent claudication. Systematic reviews have demon-
strated superiority of supervised ET (SET) over unsupervised ET for both
increasing pain-free and maximum walking distance (Bendermacher BL et
al, Cochrane Database Syst Rev 2006;CD005263; and Wind J et al, Eur
J Vasc Endovasc Surg 2007;34:1-9). A Cochran review (Fowkes FG et al,
Cochrane Database Syst Rev 2000;CD000017) indicted that there was
greater short-term beneﬁt with PTA than with exercise in patients with
intermittent claudication but that the effect was not sustained after 1 to 2
years. A second review found medical treatment (home or SET, plus risk
factor modiﬁcation) resulted in longer walking distances than PTA at 1 to
2 years (Wilson SE, Ann Vasc Surg 2010;24:498-502). The authors noted
that since this review, six additional randomized clinical trials have
compared PTA and ET during the past 5 years. They therefore decided
to perform a systematic review to summarize the results of all randomized
clinical trials comparing PTA with ET therapy. Their goal was to obtain
the best estimate of the relative effectiveness of these two approaches.
They performed a systematic review of relevant randomized clinical trials
identiﬁed from MEDLINE, Embase, and Cochrane Library Databases.
To be included in the review, the trial had to compare PTA with ET in
patients with intermittent claudication secondary to aortoiliac or femoral
popliteal occlusive disease, or both. There were 258 initial articles identiﬁed
with 11 (reporting data on eight trials) meeting inclusion criteria. There was
one trial with isolated aortoiliac obstruction, three trials with femoropopli-
teal disease, and ﬁve with combined lesions. Two trials compared PTA with
advice for ET, 4 trials compared PTA with SET, 2 trials compared PTA plus
SET with SET alone, and 2 trials compared PTA plus SET with PTA alone.
The authors concluded that heterogeneity precluded pooling of the data
even though the end points in most trials were walking distance and quality
of life. Their analysis indicated the effectiveness of PTA and ET was equiv-
alent, although PTA plus ET provided greater improvement of walking
distance and some domains of quality of life analysis compared with PTA
alone or ET alone.
Comment: The article does indeed provide a good summary of the
most up-to-date information currently available on the effectiveness of
ET and PTA in patients treated for intermittent claudication. The data
suggest that SET and PTA can both be effective in improving walking
distance in patients with claudication. Neither therapy is perfect. ET is
noninvasive, seemingly relatively inexpensive, and with less risk compared
with PTA. However, PTA may be more universally applicable and more
quickly effective than ET. Eventual failure rates are high with PTA treat-
ment of femoral popliteal disease, but angioplasty of infrainguinal arteries
is a moving target, with improvements of percutaneous techniques, such
as drug-eluting balloons and stents, potentially shortly down the road.
Two important questions not addressed in this study include the cost effec-
tiveness of each treatment strategy and the potential for each treatment
strategy to convert patients from claudication to critical limb ischemia
with therapy failure.
